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PBSCT may be an attractive treatment option for patients with
POEMS syndrome. Methods: Between March 1999 and February
2003, 11 patients with POEMS syndrome underwent PBSCT at
Mayo Clinic Rochester and Jacksonville. Conditioning regimens
were single agent melphalan (n  9) and BEAM (n  1). All
received a minimum of 4.4  106 CD34 autologous PBSC/kg.
Standard supportive care with prophylactic antibiotics and growth
factor support was provided. Results: All but one had a severe
rapidly progressive sensorimotor PN involving both upper and
lower extremities, 7 wheelchair conﬁned. One patient had sensory
neuropathy without signiﬁcant motor involvement. All but one was
male. A monoclonal lambda PCD was documented in all patients,
and two had biopsy proven Castleman Disease. Median age was 50
years (range 19-62). Seven had organomegaly (5 splenomegaly; 2
hepatomegaly; and 3 lymphadenopathy). Both endocrinopathy and
skin changes were present in 9 patients. Seven had thrombocytosis
and/or erythrocytosis, and 8 had sclerotic bone lesions (diffuse in 5,
solitary lesion in 3). Using the Bardwick Criteria, the median
number of POEMS features was 5 (range 2-5). The median num-
ber of therapeutic regimens prior to PBSCT was 3 (range 0-6).
From ﬁrst symptoms and from diagnosis of POEMS the median
times to transplant were 27 and 10 months (ranges 4-180 and
2-180), respectively. All but one patient had signiﬁcantly abnormal
pre-transplant pulmonary function tests. Of the 8 evaluable pa-
tients, all have had a hematologic response and 7 have had neuro-
logic improvement at a median follow-up of 6 months. Other
symptoms including fatigue, organomegaly, pulmonary compro-
mise, hyperpigmentation and extravascular volume overload have
improved substantially in affected patients. Since February 2003,
an additional 4 patients have been transplanted, but are not yet
evaluable. Conclusions: PBSCT for POEMS syndrome may re-
sult in a high hematologic response rate and improvement in
peripheral neuropathy and systemic symptoms. The outcome of
these patients will be updated at the meeting.
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GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE AFTER AUTOLO-
GOUS STEM CELL TRANSPLANT: INCIDENCE, OUTCOME, AND RISK
FACTORS
Holmberg, L.A.1,2, Gooley, T.1,2, Kikuchi, K.1, Adams, K.M.1,2, Schoch,
G.H.1,2, Bensinger, W.I.1,2, McDonald, G.B.1,2 1. Fred Hutchinson
Cancer Research Center, Seattle, WA; 2. University of Washington,
Seattle, WA
GVHD has been described in the skin, intestinal mucosa, and
liver after autologous stem cell transplantation. The mechanisms
and risk factors for non-cyclosporine-induced autologous GVHD
are unknown. Methods: We reviewed 681 consecutive autologous
transplant patients treated between 1995–1999 to determine the
incidence of response to treatment, and risk factors for developing
gastrointestinal GVHD. GVHD was deﬁned by persistent symp-
toms, mucosal abnormalities at endoscopy, histology showing ap-
optotic crypt-cells and lymphoid inﬁltrates, and absence of infec-
tion. Results: The incidence of GVHD was 90/681 (13%), with
nausea, vomiting, and anorexia in 90% and diarrhea in 37%. The
mean time to onset was day  15 and endoscopic diagnosis day 
45. Treatment with prednisone (1 mg/kg/d) for 10-14 days fol-
lowed by a taper effected durable responses in 72%; an additional
19% responded to a second course. GVHD developed in 18% of
the women and 8% of the men. Signiﬁcant risk factors in univariate
analysis included female sex (p  .0009), diagnosis of breast cancer
(BRCA) (p  .0001), IL-2 therapy (p  .04), Busulfan/Melphalan/
Thiotepa (BUMELTT) conditioning (p  .03) and use of PBSC
(p  .025). All cases of GVHD were in patients who received
PBSCs. Females with BRCA were 3.3x more likely to develop
GVHD than males with any diagnosis (95% C.I., 1.9-5.8, p 
.0001). Gravidity and parity of females did not statistically affect
the risk for developing GVHD. Since women were more likely to
receive BUMELTT conditioning, the data was analyzed adjusting
for this regimen. A multivariate logistic regression model revealed
the following: (see Table 1)
The hazard of mortality (or relapse) of patients with GVHD
compared to those without was not signiﬁcantly different for the
cohort as a whole nor across different genders/diagnoses (HR:
0.89, 95% C.I. 0.64-1.22, p  .46). Conclusions: Gastrointestinal
GVHD developed in 13% of 681 autologous transplant recipients
and was responsive to short courses of prednisone. Female sex
appears to be the most important risk factor. Although
BUMELTT appears to increase the odds of developing GVHD,
female gender and underlying disease carried an increased risk for
developing GVHD independent of the conditioning regimen.
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SIGNIFICANCE OF LOW PERIPHERAL BLOOD CD34 CELL NUMBERS
PRIOR TO LEUKAPHERESIS: SHOULD THE 5/L THRESHOLD RE-
QUIRED FOR APHERESIS BE CHANGED?
Gidron, A., Doyle, M., Gordon, L., Singhal, S., Tallman, M., Williams,
S., Winter, J., Tomblyn, M., Verma, A., Mehta, J. Northwestern
University, Chicago
The pre-apheresis peripheral blood CD34 cell count
(PBCD34) is a strong predictor of the CD34 cell collection. The
ﬁnal yield is also affected by the blood volume processed and the
CD34 cell collection efﬁciency (CE). It is common practice to
apherese only when PBCD34 is 5/L to avoid poor yields. How-
ever, many patients mobilize stem cells poorly, and the only way to
get enough cells is to collect small numbers at a time over several
days. Omitting apheresis because PBCD34 is below a set value may
prevent them from undergoing a transplant. There are other pit-
falls with this practice: it does not take the patient’s weight into
account, and it ignores the possibility of improving the collection
by processing more blood. Of 485 autologous harvests on Cobe
Spectra over 30 months where PBCD34 was available, 104 were
done with PBCD34 5/L. Volume processed was 15 L (n  57)
or 20 L (n  47). A collection of 0.3  106 CD34 cells/kg was
considered acceptable as this daily yield over a week could add up
to 2  106/kg-enough for an autograft. 60 harvests (58%) had
yields of 0.3; with 49% being 0.4, 38% being 0.5 and 23%
being 0.6. CE for these 104 harvests was 9-145% (median 55%)
compared to 7-132% (median 45%) for the other 381 harvests
performed with PBCD34 5/L (P  0.0001). CE for the 60
harvests with CD34 yields 0.3 was 30-145% (median 70) com-
pared with 9-118% (median 35%) for the 44 with CD34 yields
0.3 (P  0.0001). This suggests that part of the reason for poor
collection was low CE in addition to poor mobilization. The
problem of low CE may be solved in part by using more experi-
enced operators if the mononuclear cell protocol is used for
apheresis or using an automated collection protocol such as
AutoPBSC. These data show that an arbitrary PBCD34 threshold
of 5/L is inappropriate to deny apheresis. We suggest using the
following formula for patients with PBCD34 5/L to decide
about appropriateness of apheresis: 14n/w; where n 
PBCD34/L and w  ideal body weight in kg. A 20 L apheresis
with 70% CE is assumed (20  0.7  14). If 14n/w is 0.3,
apheresis should be performed. This approach is more logical than
using an absolute threshold, and ensures that patients are not
deprived of the opportunity of stem cell collection and autotrans-
plantation. We conclude that it is clinically inappropriate to set an
arbitrary minimum PBCD34 threshold for apheresis. This practice
Table.
Gender/diagnosis O.R. 95% C.I. P Value
Male/lymphoma, myeloma, or hem.
malignancy 1 — —
Female/BRCA 3.4 1.8-6.6 .0002
Female/lymphoma, myeloma, or hem.
malignancy 2.9 1.4-6.0 .003
Male/other diagnoses 3.0 1.2-7.5 .02
Female/other diagnoses 2.2 0.9-5.5 .08
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